Compare Pfizer Inc (PFE) vs Vistra Corp (VST) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Vistra Corp (VST) trades at $157.99, up 1.64% with strong institutional support and bullish technical signals. The stock shows robust fundamentals with 74.92% ROE and 11.52% net margin, though recent earnings were mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Analyst consensus remains overwhelmingly positive with 91% buy ratings and a $253 price target, representing 60% upside potential. Recent news highlights Vistra's positioning in the AI power infrastructure boom and long-term power purchase agreements with major tech companies.

Vistra presents significant growth potential driven by AI infrastructure demand and nuclear energy expansion, but faces risks from power price volatility and high debt levels. The company's diversified utility operations and strategic PPAs provide revenue stability, while technical indicators suggest continued upward momentum with key resistance at $159-$162. Investors should weigh the strong analyst support against execution risks in capital-intensive energy projects.